

3. Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. *Ann Allergy Asthma Immunol* 2019;123(6):564-572.e.3.
4. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. *J Allergy Clin Immunol* 2003;111:1212-1218.
5. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014 Feb;43(2):343-73.
6. Skov I.R., Madsen H., Henriksen D.P., Andersen J.H., Pottegård A., Davidsen J.R. Low dose oral corticosteroids in asthma associates with increased morbidity and mortality. *Eur Respir J*. 2022;60(3)
7. Heatley H., Tran T.N., Bourdin A., et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. *Thorax*. 2023;78(9):860-867.
8. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. *N Engl J Med*. 2022 Jan 13;386(2):157-171.
9. Hanania N.A., Wenzel S., Rosen K., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med*. 2013;187(8):804-811.
10. Casale T.B., Luskin A.T., Busse W., et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. *J Allergy Clin Immunol Pract*. 2019;7(1):156-164.e1.
11. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. *J Allergy Clin Immunol* 2003;111:714-719.
12. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med* 2014;371:1198-1207.
13. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet*. 2012 Aug 18;380(9842):651-9.
14. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3 b trial. *Lancet Respir Med* 2017;5:390-400.
15. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014 Sep 25;371(13):1189-97.
16. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaitis S, Yang S, Howarth P, Van Dyke MK. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. *Eur Respir J*. 2020 Oct 15;56(4):2000151.
17. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting  $\beta_2$ -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016 Oct 29;388(10056):2115-2127.
18. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor  $\alpha$  monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016 Oct 29;388(10056):2128-2141.
19. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. *N Engl J Med*. 2017;376(25):2448-2458.
20. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med*. 2018;378(26):2486-2496.
21. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med*. 2018;378(26):2475-2485.
22. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med*. 2021.
23. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOUR-CE): a randomised, placebo-controlled, phase 3 study. *Lancet Respir Med*. 2022;10(7):650-660.
24. Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. *Chest*. 2025 Feb;167(2):330-342.
25. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. *J Allergy Clin Immunol*. 2021 Sep;148(3):790-798.
26. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. *N Engl J Med*. 2021 Oct 28;385(18):1656-1668.
27. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. *N Engl J Med*. 2024 Dec 19;391(24):2337-2349.

## ON-LINE KURZ

# Medicína pro praxi

# 1 2025

## OBSAH KURZU

- ▶ **Management MASLD – diagnostika jaterní fibrózy v primární péči**  
MUDr. Václav Šmíd, Ph.D.
- ▶ **21. století: nastal čas pro optimální suplementaci železem**  
doc. MUDr. Jiří Slíva, Ph.D., MBA
- ▶ **Broncho-Vaxom v prevenci opakovaných respiračních infekcí**  
MUDr. Mojmír Račanský  
*Přednáška sponzorovaná společností 4 Life Pharma CZ, s.r.o.*
- ▶ **Cestovní medicína pro praxi – MUDr. Milan Trojánek, Ph.D.**

## ODBORNÝ GARANT:

MUDr. Pavel Rutar

Interní oddělení, Nemocnice Na Homolce, Praha

## POŘADATEL:

Společnost SOLEN, s. r. o., ve spolupráci s Interním oddělením, Nemocnice Na Homolce

POČET  
KREDITŮ **2**

Registrace  
ZDARMA

TERMÍN  
květen 2025  
až duben 2026  
dostupný na  
[online.solen.cz](https://online.solen.cz)

PARTNEŘI:

